MX2014014531A - Derivados de aminoquinazolina y piridopirimidina. - Google Patents
Derivados de aminoquinazolina y piridopirimidina.Info
- Publication number
- MX2014014531A MX2014014531A MX2014014531A MX2014014531A MX2014014531A MX 2014014531 A MX2014014531 A MX 2014014531A MX 2014014531 A MX2014014531 A MX 2014014531A MX 2014014531 A MX2014014531 A MX 2014014531A MX 2014014531 A MX2014014531 A MX 2014014531A
- Authority
- MX
- Mexico
- Prior art keywords
- aminoquinazoline
- pyridopyrimidine derivatives
- compounds
- pyridopyrimidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La invención proporciona nuevos compuestos que tienen la fórmula general: (ver Fórmula) en donde A, R1 R2 y R3 son como se define en la presente, incluyendo las composiciones los compuestos y métodos para utilizar los compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653812P | 2012-05-31 | 2012-05-31 | |
PCT/EP2013/060884 WO2013178591A1 (en) | 2012-05-31 | 2013-05-27 | Aminoquinazoline and pyridopyrimidine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014014531A true MX2014014531A (es) | 2015-04-08 |
Family
ID=48536860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014531A MX2014014531A (es) | 2012-05-31 | 2013-05-27 | Derivados de aminoquinazolina y piridopirimidina. |
Country Status (11)
Country | Link |
---|---|
US (3) | US9382241B2 (es) |
EP (1) | EP2855459B1 (es) |
JP (1) | JP6231085B2 (es) |
KR (1) | KR20150020228A (es) |
CN (1) | CN104507933B (es) |
BR (1) | BR112014029404A2 (es) |
CA (1) | CA2870407A1 (es) |
HK (1) | HK1209107A1 (es) |
MX (1) | MX2014014531A (es) |
RU (1) | RU2014149684A (es) |
WO (1) | WO2013178591A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014029404A2 (pt) * | 2012-05-31 | 2017-06-27 | Hoffmann La Roche | compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção |
WO2015076310A1 (ja) | 2013-11-20 | 2015-05-28 | 株式会社 三和化学研究所 | 新規3-アザビシクロ[3.1.0]ヘキサン誘導体及びその医薬用途 |
CN115925711A (zh) | 2014-11-06 | 2023-04-07 | Bial研发投资股份有限公司 | 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途 |
CA2966581A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
WO2016089977A1 (en) * | 2014-12-03 | 2016-06-09 | Celgene Corporation | Substituted indazole compounds, compositions thereof, and methods of treatment therewith |
MX2018012208A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
WO2017176962A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics, Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
CN109311887B (zh) | 2016-04-06 | 2022-09-13 | Bial研发投资股份有限公司 | 吡唑并[1,5-a]嘧啶基甲酰胺化合物以及它们在治疗医学病症中的用途 |
WO2017192929A1 (en) * | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
EP3452481A4 (en) | 2016-05-05 | 2020-02-26 | Lysosomal Therapeutics Inc. | IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
CN108239076B (zh) * | 2016-12-26 | 2021-07-06 | 中国医学科学院药物研究所 | 喹唑啉类化合物及其制备方法、用途和药物组合物 |
WO2019081485A1 (de) | 2017-10-26 | 2019-05-02 | Bayer Cropscience Aktiengesellschaft | Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
WO2019081477A1 (de) | 2017-10-26 | 2019-05-02 | Bayer Cropscience Aktiengesellschaft | Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
US20220127249A1 (en) * | 2019-02-22 | 2022-04-28 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
BR112022016072A2 (pt) * | 2020-02-17 | 2022-10-04 | Alesta Therapeutics BV | Compostos moduladores de gcn2, sal farmaceuticamente aceitável, seus usos, e composição farmacêutica |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB696692A (en) | 1950-12-06 | 1953-09-09 | Ici Ltd | New quinazoline derivatives |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE51802B1 (en) * | 1979-12-03 | 1987-04-01 | Fujisawa Pharmaceutical Co | Quinazoline derivatives,processes for their preparation and pharmaceutical compositions containing them |
JPS5695174A (en) * | 1979-12-03 | 1981-08-01 | Fujisawa Pharmaceut Co Ltd | Quinazoline derivative |
US4377530A (en) | 1982-03-05 | 1983-03-22 | American Cyanamid Company | Manufacture of isocyanates |
SI20582A (sl) * | 2000-05-05 | 2001-12-31 | Univerza V Ljubljani | Novi inhibitorji trombina, njihova priprava in uporaba |
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
EP1734040A4 (en) * | 2004-03-23 | 2007-11-28 | Banyu Pharma Co Ltd | SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
JP2008516962A (ja) * | 2004-10-15 | 2008-05-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管傷害を治療する方法 |
ES2371397T3 (es) | 2005-06-22 | 2011-12-30 | Plexxikon, Inc. | Derivados de pirrolo[2,3-b]piridina como inhibidores de proteínas cinasas. |
CA2612788A1 (en) * | 2005-06-24 | 2006-12-28 | Steven Cesar Alfons De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c |
DE102006012251A1 (de) * | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
WO2008080015A2 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
GB0714602D0 (en) | 2007-07-26 | 2007-09-05 | Novathera Ltd | Process |
KR20110007235A (ko) * | 2008-05-01 | 2011-01-21 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 퀴놀린 및 관련 유사체 |
WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
WO2012125668A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
BR112014029404A2 (pt) * | 2012-05-31 | 2017-06-27 | Hoffmann La Roche | compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção |
CN104409057B (zh) * | 2014-11-14 | 2017-09-29 | 深圳市华星光电技术有限公司 | 一种扫描驱动电路 |
-
2013
- 2013-05-27 BR BR112014029404A patent/BR112014029404A2/pt not_active IP Right Cessation
- 2013-05-27 CN CN201380040547.8A patent/CN104507933B/zh not_active Expired - Fee Related
- 2013-05-27 EP EP13725654.1A patent/EP2855459B1/en active Active
- 2013-05-27 JP JP2015514452A patent/JP6231085B2/ja not_active Expired - Fee Related
- 2013-05-27 WO PCT/EP2013/060884 patent/WO2013178591A1/en active Application Filing
- 2013-05-27 RU RU2014149684A patent/RU2014149684A/ru not_active Application Discontinuation
- 2013-05-27 MX MX2014014531A patent/MX2014014531A/es unknown
- 2013-05-27 CA CA2870407A patent/CA2870407A1/en not_active Abandoned
- 2013-05-27 KR KR1020147036895A patent/KR20150020228A/ko not_active Application Discontinuation
- 2013-05-31 US US13/906,626 patent/US9382241B2/en active Active
-
2015
- 2015-10-06 HK HK15109734.5A patent/HK1209107A1/xx not_active IP Right Cessation
-
2016
- 2016-06-16 US US15/184,310 patent/US9592235B2/en active Active
-
2017
- 2017-03-09 US US15/454,793 patent/US9855269B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2855459B1 (en) | 2020-04-29 |
RU2014149684A (ru) | 2016-07-20 |
US20170173026A1 (en) | 2017-06-22 |
JP2015522552A (ja) | 2015-08-06 |
CN104507933A (zh) | 2015-04-08 |
US9855269B2 (en) | 2018-01-02 |
US9382241B2 (en) | 2016-07-05 |
US20130324516A1 (en) | 2013-12-05 |
CN104507933B (zh) | 2017-10-31 |
US9592235B2 (en) | 2017-03-14 |
WO2013178591A1 (en) | 2013-12-05 |
CA2870407A1 (en) | 2013-12-05 |
JP6231085B2 (ja) | 2017-11-15 |
US20160296525A1 (en) | 2016-10-13 |
HK1209107A1 (en) | 2016-03-24 |
BR112014029404A2 (pt) | 2017-06-27 |
EP2855459A1 (en) | 2015-04-08 |
KR20150020228A (ko) | 2015-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014014531A (es) | Derivados de aminoquinazolina y piridopirimidina. | |
PH12015500263A1 (en) | New bicyclic derivatives | |
PH12014502697A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
PH12017500408A1 (en) | Heteroaryl compunds as btk inhibitors and uses thereof | |
PH12014501179B1 (en) | New bicyclic dihydroisoquinoline-1-one derivatives | |
MX2014002770A (es) | Nuevos derivados dihidroquinolina-2-ona. | |
PH12015500347A1 (en) | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
MY169267A (en) | New aryl-quinoline derivatives | |
AU2012213775A8 (en) | 7-azaindole derivatives | |
MX2014001879A (es) | Aminoquinazolinas como inhibidores de quinasa. | |
MX2014002624A (es) | Nuevos derivados biciclicos de dihidroquinolina-2-ona. | |
EP2566477A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
MX2015001099A (es) | Nuevos derivados biciclicos de piridina. | |
MY186599A (en) | Substituted pyridopyrazines as novel syk inhibitors | |
MX2015007097A (es) | Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer. | |
MX2012008141A (es) | Compuestos y metodos. | |
PH12015500345A1 (en) | Amino-quinolines as kinase inhibitors | |
PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
MX353190B (es) | Derivados de isoquinolina y naftiridina. | |
PH12015500363A1 (en) | Prodrugs of amino quinazoline kinase inhibitor | |
CR20140495A (es) | 5-amino[1,4]thiazines como inhibidores de bace1 | |
MX2013009388A (es) | Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl). | |
MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
MX346980B (es) | Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona. |